Today was the day announced for a decision to be made.
The HSE’s Senior Management Team have approved the reimbursement of Skyclarys for patients with Friedreich’s Ataxia.
Today (25 August) was the day announced for a decision to be made.
HSE senior management met to discuss providing Skyclarys, as Biogen had made a new offer to the Health Service.
The outcome will result in strong engagement with Biogen over the coming years in respect of the treatment of Friedreich’s Ataxia.
The HSE's Drugs Group earlier this month recommended the drug not be reimbursed, over cost-effectiveness concerns.
Skyclarys is the first treatment for the condition, which is shown to slow the symptoms by up to 50pc.
Kfm news had previously spoken to Niamh Ní Hoireabhaird about her experiences with FA, and Craig Coady, a father of two teenage boys have suffered with the disease, one of whom sadly passed away as a result.
The progressive neuro muscular disease causes nerve damage, muscle weakness and mobility loss.
Approximately 200 people are affected by the disease in Ireland.
Further Measures To Combat Fuel Poverty May Be Considered In Upcoming Budget
Over Half Of Under 35s Believe They Will Never Be Able To Buy A Home
Louth Woman Charged With Organised Crime Group Involvement After Weapons Seized On Friday
Over 3,000 Children In Kildare Remain On Waiting Lists For Early Years Places
Kildare Minister Urges Homeowners To Rent Spare Room For New Academic Year
Hosepipe Ban Extended For Kildare And Twelve Other Counties
7% Rise In Kildare Rents Since This Time Last Year
Wholesale Electricity Prices 56.2% Higher Than Last Year
